4,357 research outputs found

    Using Self-Disclosure to Manage Student Misconceptions in a Human Sexuality Classroom

    Get PDF
    This paper explores how three Human Development graduate student instructors of human sexuality have utilized student perception and instructor disclosure to challenge assumptions and misconceptions about sexuality. Three modes of pedagogy, culturally responsive pedagogy, experiential learning theory, and queer pedagogy, are discussed in order to illustrate the interplay of perception and disclosure when teaching. The authors provide a list of questions for instructors to be reflective as well as strategies to respond to student misconceptions about sexuality topics in the classroom.Keywords: culturally responsive pedagogy, disclosure, experiential learning theory, queer pedagogy, sexualit

    The behavioral immune system: Current concerns and future directions

    Full text link
    The behavioral immune system is a motivational system that helps minimize infection risk by changing cognition, affect, and behavior in ways that promote pathogen avoidance. In the current paper, we review foundational concepts of the behavioral immune system and provide a brief summary of recent social psychological research on this topic. Next, we highlight current conceptual and empirical limitations of this work and delineate important questions that have the potential to drive major advances in the field. These questions include predicting the ontological development of the behavioral immune system, specifying the relationship between this system and the physiological immune system, and distinguishing conditions that elicit direct effects of situational pathogen threats versus effects that occur only in interaction with dispositional disease concerns. This discussion highlights significant challenges and underexplored topics to be addressed by the next generation of behavioral immune system research.Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/142457/1/spc312371.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/142457/2/spc312371_am.pd

    Live Fast, Die Young: GMC lifetimes in the FIRE cosmological simulations of Milky Way-mass galaxies

    Get PDF
    We present the first measurement of the lifetimes of giant molecular clouds (GMCs) in cosmological simulations at z = 0, using the Latte suite of FIRE-2 simulations of Milky Way (MW) mass galaxies. We track GMCs with total gas mass ≳10⁵ M⊙ at high spatial (∼1 pc), mass (7100 M⊙), and temporal (1 Myr) resolution. Our simulated GMCs are consistent with the distribution of masses for massive GMCs in the MW and nearby galaxies. We find GMC lifetimes of 5–7 Myr, or 1–2 freefall times, on average, with less than 2 per cent of clouds living longer than 20 Myr. We find decreasing GMC lifetimes with increasing virial parameter, and weakly increasing GMC lifetimes with galactocentric radius, implying that environment affects the evolutionary cycle of GMCs. However, our GMC lifetimes show no systematic dependence on GMC mass or amount of star formation. These results are broadly consistent with inferences from the literature and provide an initial investigation into ultimately understanding the physical processes that govern GMC lifetimes in a cosmological setting

    Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis

    Get PDF
    Supported by the Global Alliance for TB Drug Development with support from the Bill and Melinda Gates Foundation, the European and Developing Countries Clinical Trials Partnership, U.S. Agency for International Development, U.K. Department for International Development, Directorate General for International Cooperation of the Netherlands, Irish Aid, Australia Department of Foreign Affairs and Trade, and National Institutes of Health, AIDS Clinical Trials Group and by grants from the National Institute of Allergy and Infectious Diseases (NIAID) (UM1AI068634, UM1 AI068636, and UM1AI106701) and by NIAID grants to the University of KwaZulu Natal, South Africa, AIDS Clinical Trials Group (ACTG) site 31422 (1U01AI069469); to the Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, South Africa, ACTG site 12301 (1U01AI069453); and to the Durban International Clinical Trials Unit, South Africa, ACTG site 11201 (1U01AI069426); Bayer Healthcare for the donation of moxifloxacin; and Sanofi for the donation of rifampin.Background: Early-phase and preclinical studies suggest that moxifloxacin-containing regimens could allow for effective 4-month treatment of uncomplicated, smear-positive pulmonary tuberculosis. Methods: We conducted a randomized, double-blind, placebo-controlled, phase 3 trial to test the noninferiority of two moxifloxacin-containing regimens as compared with a control regimen. One group of patients received isoniazid, rifampin, pyrazinamide, and ethambutol for 8 weeks, followed by 18 weeks of isoniazid and rifampin (control group). In the second group, we replaced ethambutol with moxifloxacin for 17 weeks, followed by 9 weeks of placebo (isoniazid group), and in the third group, we replaced isoniazid with moxifloxacin for 17 weeks, followed by 9 weeks of placebo (ethambutol group). The primary end point was treatment failure or relapse within 18 months after randomization. Results: Of the 1931 patients who underwent randomization, in the per-protocol analysis, a favorable outcome was reported in fewer patients in the isoniazid group (85%) and the ethambutol group (80%) than in the control group (92%), for a difference favoring the control group of 6.1 percentage points (97.5% confidence interval [CI], 1.7 to 10.5) versus the isoniazid group and 11.4 percentage points (97.5% CI, 6.7 to 16.1) versus the ethambutol group. Results were consistent in the modified intention-to-treat analysis and all sensitivity analyses. The hazard ratios for the time to culture negativity in both solid and liquid mediums for the isoniazid and ethambutol groups, as compared with the control group, ranged from 1.17 to 1.25, indicating a shorter duration, with the lower bounds of the 95% confidence intervals exceeding 1.00 in all cases. There was no significant difference in the incidence of grade 3 or 4 adverse events, with events reported in 127 patients (19%) in the isoniazid group, 111 (17%) in the ethambutol group, and 123 (19%) in the control group. Conclusions: The two moxifloxacin-containing regimens produced a more rapid initial decline in bacterial load, as compared with the control group. However, noninferiority for these regimens was not shown, which indicates that shortening treatment to 4 months was not effective in this setting. (Funded by the Global Alliance for TB Drug Development and others; REMoxTB ClinicalTrials.gov number, NCT00864383.)Publisher PDFPeer reviewe

    Rural Appalachian Women Will Suffer Disproportionately if Attempts to Further Restrict Emergency Contraception are Successful

    Get PDF
    The removal of federal abortion protection has incited fear that restrictions on contraception may be next. Many states now imposing abortion restrictions and bans are in the South and Appalachian Regions of the U.S., where rates of unplanned pregnancy and poor health outcomes are already disproportionately high. Numerous studies have documented variable access to levonorgestrel EC (LNG EC) in community pharmacies, with particularly low rates of access at independent pharmacies that are more likely to be located in rural communities than chain pharmacies. Since the overturn of Roe v. Wade, some large chain pharmacies and online retailers are restricting the purchase of LNG EC, limiting its availability. Some legislators and activists are calling for a ban on EC based on a misunderstanding about its mechanism of action, equating it with abortion. At a time when access to the full range of contraceptive options is more critical than ever, already limited access to LNG EC is worsening. Extensive data on LNG EC availability in 509 pharmacies and 400 health clinics across West Virginia, contextualized with socioeconomic demographics, illustrate existing disparities in LNG EC access

    Implicitly imprinting the past on the present: Automatic partner attitudes and the transition to parenthood

    Get PDF
    A new model is proposed to explain how automatic partner attitudes affect how couples cope with major life transitions. The Automatic Partner Attitudes in Transition (APAT) model assumes that people simultaneously possess contextualized automatic attitudes toward their partner that can differ substantively in valence pre- and post-transition. It further assumes that evaluatively inconsistent pre- and post-transition automatic partner attitudes elicit heightened behavioral angst or uncertainty, self-protective behavior in response to risk, and relationship distress. A longitudinal study of the transition to first parenthood supported the model. People with evaluatively inconsistent automatic partner attitudes, whether more negative pre-transition and positive post-transition, or more positive pre-transition and negative post-transition, exhibited heightened evidence of cardiovascular threat discussing conflicts, increased self-protective behavior in response to parenting-related transgressions in daily interaction, and steeper declines in relationship well-being in the year following the transition to parenthood

    Reproducing the CO-to-H₂ conversion factor in cosmological simulations of Milky-Way-mass galaxies

    Get PDF
    We present models of CO(1–0) emission from Milky-Way-mass galaxies at redshift zero in the FIRE-2 cosmological zoom-in simulations. We calculate the molecular abundances by post-processing the simulations with an equilibrium chemistry solver while accounting for the effects of local sources, and determine the emergent CO(1–0) emission using a line radiative transfer code. We find that the results depend strongly on the shielding length assumed, which, in our models, sets the attenuation of the incident UV radiation field. At the resolution of these simulations, commonly used choices for the shielding length, such as the Jeans length, result in CO abundances that are too high at a given H₂ abundance. We find that a model with a distribution of shielding lengths, which has a median shielding length of ∼3 pc in cold gas (T < 300 K) for both CO and H₂, is able to reproduce both the observed CO(1–0) luminosity and inferred CO-to-H₂ conversion factor at a given star formation rate compared with observations. We suggest that this short shielding length can be thought of as a subgrid model, which controls the amount of radiation that penetrates giant molecular clouds

    Twenty-Four-Month Longitudinal Study Suggests Little to No Horizontal Gene Transfer In Situ between Third-Generation Cephalosporin-Resistant \u3ci\u3eSalmonella\u3c/i\u3e and Third-Generation Cephalosporin-Resistant \u3ci\u3eEscherichia coli\u3c/i\u3e in a Beef Cattle Feedyard

    Get PDF
    Third-generation cephalosporins (3GCs) are preferred treatments for serious human Salmonella enterica infections. Beef cattle are suspected to contribute to human 3GC-resistant Salmonella infections. Commensal 3GC-resistant Escherichia coli are thought to act as reservoirs of 3GC resistance because these strains are isolated more frequently than are 3GC-resistant Salmonella strains at beef cattle feedyards. During each of 24 consecutive months, four samples of pen surface material were obtained from five pens (N = 480) at a Nebraska feedyard to determine to the contribution of 3GC-resistant E. coli to the occurrence of 3GC-resistant Salmonella. Illumina whole genome sequencing was performed, and susceptibility to 14 antimicrobial agents was determined for 121 3GC-susceptible Salmonella, 121 3GC-resistant Salmonella, and 203 3GCresistant E. coli isolates. 3GC-susceptible Salmonella isolates were predominantly from serotypes Muenchen (70.2%) and Montevideo clade 1 (23.1%). 3GC-resistant Salmonella isolates were predominantly from serotypes Montevideo clade 2 (84.3%). One bla gene type (blaCMY-2) and the IncC plasmid replicon were present in 100 and 97.5% of the 3GC-resistant Salmonella, respectively. Eleven bla gene types were detected in the 3GC-resistant E. coli, which were distributed across 42 multilocus sequence types. The blaCMY-2 gene and IncC plasmid replicon were present in 37.9 and 9.9% of the 3GC-resistant E. coli, respectively. These results suggest that 3GC resistance in Salmonella was primarily due the persistence of Salmonella Montevideo clade 2 with very minimal or no contribution from 3GC-resistant E. coli via horizontal gene transfer and that 3GCresistant E. coli may not be a useful indicator for 3GC-resistant Salmonella in beef cattle production environments
    corecore